(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...
Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...
These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...
Cancer. https://doi.org/10.1002/cncr.35612, December 2024. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review ...
Founded by a multidisciplinary team of experts, US Prostate Cancer Conferences seeks to connect thought leaders from academia, community practice, and industry to accelerate progress in the diagnosis, ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Male infertility is a prevalent global health issue, with urological disorders representing some of the most common and correctable causes. Key conditions such as varicocele, obstructive azoospermia, ...
Alan Wein: Hello, it's Alan Wein from UroToday. And today we have a special treat for you all the way from Japan, Professor Yoshiyuki Akiyama, who's the professor and chair of the Department of ...
Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients - Paul Nguyen
Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. Validation using RTOG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results